Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

7.545
-0.905-10.71%
Volume:4.17M
Turnover:32.11M
Market Cap:7.94B
PE:-20.39
High:8.455
Open:8.455
Low:7.395
Close:8.450
52wk High:19.860
52wk Low:7.395
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:2.89
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-28.59%
ROA:-19.64%
PB:2.99
PE(LYR):-20.39
PS:7159.24

Loading ...

Ascletis Pharma Holds Annual Shareholder Meeting

Reuters
·
Jun 29

Ascletis Pharma Shareholders Approve Amended and Restated Bylaws

Reuters
·
Jun 29

ASCLETIS-B Shares Surge Over 7% on FDA IND Approval for ASC35 Phase I Study and GIC's Consistent Share Purchases

Stock News
·
Jun 29

Ascletis executes HKD 1.93 million on-market share buyback; outstanding share count steady at 1.07 billion

Bulletin Express
·
Jun 26

Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jun 26

Is Ascletis Pharma (SEHK:1672) Undervalued On FDA Clearance For ASC35?

Simply Wall St.
·
Jun 24

ASCLETIS PHARMA CONDUCTS HK$2.02 MILLION SHARE BUYBACK

Stock News
·
Jun 24

Ascletis Pharma Gets US FDA Nod for Obesity Drug Trial

MT Newswires Live
·
Jun 23

ASCLETIS-B Receives FDA Clearance for Phase I Study of Its Monthly Subcutaneous GLP-1R/GIPR Dual Agonist Peptide ASC35 in Obesity

Stock News
·
Jun 23

Ascletis Announces U.S. FDA Ind Clearance for Phase I Study of Once-Monthly Subcutaneously Administered Glp-1R/Gipr Dual Peptide Agonist, Asc35, for the Treatment of Obesity

THOMSON REUTERS
·
Jun 23

Ascletis wins US FDA IND clearance for Phase I study of monthly obesity drug ASC35

Reuters
·
Jun 23

Ascletis Pharma - Receives U.S. FDA Ind Clearance for Phase I Study of Asc35 for Obesity

THOMSON REUTERS
·
Jun 23

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

ASCLETIS-B Executes Share Buyback on June 22, Spending HK$1.901 Million

Stock News
·
Jun 22

Ascletis Pharma files HKEX next-day return disclosing share repurchase for cancellation

Reuters
·
Jun 22

ASCLETIS-B Executes Share Buyback Totaling HK$1.97 Million

Stock News
·
Jun 17

Ascletis Pharma files HKEX next-day disclosure return on share repurchase for cancellation

Reuters
·
Jun 17

ASCLETIS-B Executes Share Buyback, Spending HK$1.86 Million

Stock News
·
Jun 16

Ascletis Pharma files HKEX next-day disclosure return reporting share repurchase for cancellation

Reuters
·
Jun 16

ASCLETIS-B Executes Share Buyback, Spending HK$1,918,300 on June 15

Stock News
·
Jun 15